Skip to main content
National News Desk
health

Strain-specific Ebola jab trials to start in DR Congo next week: WHO

The Hindu Health & MedicalBy The Hindu Health & Medical
21 Nov 2026
Original: English
AI Synopsis & Key Briefing

A total of 5,568 deaths out of 11,376 cases have been confirmed in the vast central African country's worst-ever Ebola outbreak, according to the WHO

Key Highlights & Official Takeaways
  • ✓A total of 5,568 deaths out of 11,376 cases have been confirmed in the vast central African country's worst-ever Ebola outbreak, according to the WHO
  • ✓A total of 5,568 deaths out of 11,376 cases have been confirmed in the vast central African country's worst-ever Ebola outbreak, according to the WHO.
  • ✓If the safety and immune response data from the Phase 2 trial pass the next stage of review, the candidate jabs can move forward to a full-scale Phase 3 trial.
  • ✓Doherty said that more than 140 people were enrolled in the Tumaini trial, with thousands of contacts ultimately expected to sign up.
Comprehensive News & Policy Report

Two potential vaccines against the deadly Ebola strain gripping the Democratic Republic of Congo are set to enter trials in the outbreak's epicentre next week, the World Health Organisation announced earlier this week.

There are currently no vaccines or treatments for the less common Bundibugyo species of Ebola behind the explosive outbreak declared in May, triggering an international public health emergency. A total of 5,568 deaths out of 11,376 cases have been confirmed in the vast central African country's worst-ever Ebola outbreak, according to the WHO.

"We expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week," WHO chief Tedros Adhanom Ghebreyesus told a press conference at the UN health agency's headquarters in Geneva.

The so-called Tumaini trial in the DRC is a single framework that can test the safety, efficacy and ability to trigger an immune response of multiple vaccines. The trial uses ring vaccination: immunising contacts deemed to be at high risk of infection.

Ervebo, a vaccine already approved for use against the more common Zaire strain of Ebola, kicked off the Tumaini trial on October 23, at the full-scale Phase 3 level, to determine if it also offers any protection against Bundibugyo.

The trial will now also incorporate the two Bundibugyo-specific candidate vaccines, which have both gone through earlier-stage, smaller-scale Phase 1 clinical trials. One is a ChAdOx1 adenoviral vector jab developed by the University of Oxford; the other, mRNA-1469, was developed by the US-based Moderna group using the mRNA technology made famous during the Covid-19 pandemic.

Meg Doherty, head of the WHO's science for health department, said Phase 2 clinical trials with the candidate vaccines are scheduled to begin on November 26 or 27 in Bunia, the capital of the DRC's northeastern Ituri province at the epicentre of the outbreak.

If the safety and immune response data from the Phase 2 trial pass the next stage of review, the candidate jabs can move forward to a full-scale Phase 3 trial. Doherty said that more than 140 people were enrolled in the Tumaini trial, with thousands of contacts ultimately expected to sign up.

The trial will also eventually expand beyond the current single site in Bunia. Ebola, which spreads through contact with bodily fluids and causes a haemorrhagic fever, has killed more than 15,000 people in Africa over the past 50 years.

Tedros said 400 to 500 new cases were still being reported every week, with two-thirds of confirmed deaths still taking place outside Ebola treatment centres. "Children are paying a terrible price. They account for more than a quarter of confirmed cases and one third of deaths," he added.

Actionable Steps for Aspirants & Citizens
  • •Aspirants and citizens are advised to monitor official notices and circulars issued by The Hindu Health & Medical.
  • •Verify all prescribed eligibility criteria, cutoff dates, and authenticated document requirements prior to formal submissions.
  • •Track connected examination timetables, vacancy advisories, and administrative gazettes on SuchnaSetu.
Official Notice Specification
Issuing AuthorityThe Hindu Health & Medical
Topic CategoryHEALTH
JurisdictionAll India / National
Publication Date21 November 2026
Connected Government Jobs & Upcoming Exams
Active on SuchnaSetu
Official Source Attribution: The Hindu Health & Medical
View Publisher Source Link

SuchnaSetu provides verified civic and public policy reports based on official notices. Primary publication and copyright remain with the respective government authority or publisher.